

## Dr. Vavvas joins OliX Pharma's Scientific Advisory Board

22 April 2019 | News | By Sonali Wankhade

### Dr. Vavvas is a distinguished scientific expert in Ophthalmology



OliX Pharmaceuticals, a leading developer of RNAi therapeutics has announced that Demetrios G. Vavvas, M.D., Ph.D., one of the world leaders in the field of Ophthalmology, has joined its Scientific Advisory Board (SAB). Dr. Vavvas is a distinguished scientific expert in Ophthalmology and has pioneered research in diabetic retinopathy, ocular tumors, and the "dry" form of age-related macular degeneration (AMD).

"We are very pleased to announce that Dr. Vavvas has joined our SAB. We will focus on developing ocular diseases with the SAB, and will advance our innovative RNAi ocular therapeutics toward the clinic." said Dong-ki Lee, Ph.D., the founder and CEO of OliX.

Dr. Vavvas currently serves as Associate Professor of Ophthalmology Harvard Medical School and Monte J. Wallace Ophthalmology Chair in Retina at The Massachusetts Eye and Ear Infirmary (MEEI). Dr. Vavvas was named one of the ophthalmologist's power list 2019. He has received over 32 awards and honors and is the author of over 183 publications and cited by others 10,400.